Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending August 31, 2019
October 25 2019 - 3:05PM
Business Wire
Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the
“Company” or “Bioasis”), a pre-clinical,
research-stage biopharmaceutical company developing its
proprietary xB3 TM platform technology for the delivery of
therapeutics across the blood-brain barrier (“BBB”) and the
treatment of central nervous system (“CNS”) disorders in areas of
high unmet medical need, including brain cancers and
neurodegenerative diseases, today announced it has filed its
audited annual financial statements and management’s discussion and
analysis for the period ended August 31, 2019. All are available
under the Company’s profile on SEDAR at www.sedar.com and on the
Company’s website at www.bioasis.us/investors/.
ABOUT BIOASIS
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 TM platform, a proprietary technology for the
delivery of therapeutics across the BBB and the treatment of CNS
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases. The delivery of
therapeutics across the BBB represents the final frontier in
treating neurological disorders. The in-house development programs
at Bioasis are designed to develop symptomatic and
disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191025005475/en/
On behalf of the Board of Directors of Bioasis Technologies
Inc. Deborah Rathjen, Ph.D., Director and President & Chief
Executive Officer deborah@bioasis.us +1 203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2024 to May 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From May 2023 to May 2024